Viking Therapeutics, Inc. (VKTX)

♥ 393 Thanks from members

Viking Therapeutics, Inc. (VKTX) exhibits a mix of wider-than-expected quarterly losses driven by heavy R&D investments and strong bullish market sentiment, with analysts highlighting potential upside targets, positive technical momentum, and persistent timeline risks.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →

Other Nasdaq Tickers

NASDAQ

Microchip Technology Incorporated (MCHP)

NASDAQ

Direxion Daily AAPL Bear 1X ETF (AAPD)

NASDAQ

Ascentage Pharma Group International - American Depository Shares (AAPG)

NASDAQ

Direxion Daily AAPL Bull 2X ETF (AAPU)

NASDAQ

Alpha Blue Capital US Small-Mid Cap Dynamic ETF (ABCS)

NASDAQ

AbCellera Biologics Inc. - Common Shares (ABCL)

Entity & Market Metadata

Sector: Health Care Industry: Biotechnology Founder: Viking Therapeutics Management Leadership: Brian Lian (CEO) Leadership: Greg Sullivan (CFO) Holder: Baker Bros. Advisors Holder: BlackRock Inc. Holder: Vanguard Group VK2735 (GLP-1/GIP receptor agonist) VK2809 (THR-beta agonist) #VKTX stock #Viking Therapeutics #biotech clinical trials #NASDAQ pharma #obesity drug stock